Advertisement Pharmaceutical Business review - Page 19 of 5253 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 5, 2025

Takeda and Innovent fulfil close conditions for ADC and IO therapies

Takeda and Innovent have closed their global partnership for next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, following the fulfilment of all closing conditions.

Continue
Takeda holds global manufacturing rights to supply IBI363 outside Greater China. Credit: Melnikov Dmitriy/Shutterstock.com.
December 5, 2025

Denali makes $275m funding agreement with Royalty Pharma

The royalty payments will conclude once a three times return is reached, or 2.5x if achieved by the first quarter of 2039. Credit: abdullah mubarak achmad /Shutterstock.com.
December 4, 2025

Formosa and Rxilient sign licensing agreement for APP13007

Formosa is a clinical stage biotechnology company focusing on oncology and ophthalmology. Credit: THICHA SATAPITANON/Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL
  2. AGC Biologics to expand cell line development with ATUM partnership
  3. Citizen Health and UCB collaborate for epilepsy drug development
  4. Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
  5. Lotus submits NDA for VIZZ in South Korea to treat presbyopia

PRESS RELEASES

Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities
Gerresheimer at CPHI Frankfurt 2025
Gerresheimer at CPHI Frankfurt 2025
Pharmaceutical Business Review
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds

Suppliers

Whitepapers

Pharmaceutical Business Review
EVERIC® Pure – The Safe Option Right from the Start
Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme